Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02710526 · ClinicalTrials.gov registry record · Phase 2
Phase II Pharmacokinetics Study of CAM2038
A Phase 2 study of Chronic Pain and Opioid Use Disorder, sponsored by Braeburn Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 3
- Study locations
NCT02710526 is a Phase 2 study of Chronic Pain and Opioid Use Disorder that has completed, run by Braeburn Pharmaceuticals. The registered enrollment target is 66 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02710526, a Phase 2 study of Chronic Pain and Opioid Use Disorder, has completed, sponsored by Braeburn Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 3
- Study locations
Study Summary
Phase II, open label, partially randomized, three treatment group study designed to evaluate the steady state pharmacokinetics of buprenorphine and norbuprenorphine following repeated subcutaneous administrations of CAM2038.
Conditions Studied
Interventions
- DRUG CAM2038
Study Locations (3)
Alabama
- Parkway Medical - Birmingham
New Jersey
- Hassman Research Institute - Berlin
Oklahoma
- The Rivus Wellness & Research Institute - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02710526
The ClinicalTrials.gov registry entry for NCT02710526 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (91% lower). The listed sponsor is Braeburn Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which CAM2038 is the first listed.
NCT02710526 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, New Jersey, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT02710526 about?
NCT02710526 is a clinical study titled "Phase II Pharmacokinetics Study of CAM2038". Phase II, open label, partially randomized, three treatment group study designed to evaluate the steady state pharmacokinetics of buprenorphine and norbuprenorphine following repeated subcutaneous administrations of CAM2038.
What is the current status of trial NCT02710526?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2015-02. Estimated completion is 2017-07-03.
What conditions does trial NCT02710526 study?
This clinical trial studies the following conditions: Chronic Pain, Opioid Use Disorder.
What interventions are being tested in trial NCT02710526?
The interventions under investigation include: CAM2038 (DRUG).
Who is sponsoring clinical trial NCT02710526?
This trial is sponsored by Braeburn Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02710526 being conducted?
This trial has 3 study locations across Alabama, New Jersey, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product
RECRUITING · Phase 2
-
The Role of Brain Dopamine in Chronic Pain
RECRUITING · Phase 2
-
Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
Dronabinol as an Adjunct for Reducing Pain
RECRUITING · Phase 2
-
Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.